Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Average Recommendation of “Hold” by Analysts

Akoya Biosciences, Inc. (NASDAQ:AKYA) has been given a consensus rating of “Hold” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $5.43.

Several research analysts have recently weighed in on AKYA shares. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target (down previously from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Canaccord Genuity Group lowered their target price on Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Craig Hallum cut Akoya Biosciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday, November 15th.

Hedge Funds Weigh In On Akoya Biosciences

A number of hedge funds have recently made changes to their positions in AKYA. GSA Capital Partners LLP boosted its position in shares of Akoya Biosciences by 87.4% during the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after acquiring an additional 144,903 shares during the last quarter. Barclays PLC lifted its stake in Akoya Biosciences by 320.9% in the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock worth $107,000 after purchasing an additional 30,095 shares in the last quarter. State Street Corp boosted its holdings in shares of Akoya Biosciences by 4.2% during the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after purchasing an additional 18,361 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after purchasing an additional 9,429 shares in the last quarter. Finally, Regal Investment Advisors LLC increased its holdings in shares of Akoya Biosciences by 64.3% in the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after purchasing an additional 7,340 shares during the last quarter. Institutional investors own 79.42% of the company’s stock.

Akoya Biosciences Trading Down 2.8 %

Akoya Biosciences stock opened at $2.39 on Monday. The business has a 50-day simple moving average of $2.55 and a two-hundred day simple moving average of $2.52. Akoya Biosciences has a 52-week low of $1.88 and a 52-week high of $6.31. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The company has a market cap of $118.46 million, a P/E ratio of -2.03 and a beta of 1.22.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.